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Abstract: Recently, immunotherapeutic approaches have shown impressive responses in a subset of
cancer patients. However, the rate of success is low and a large percentage of treated patients do not
experience clinical benefits. Therefore, additional strategies are needed to improve responses and
select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to
immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic
events that take place during immune evasion is critical to providing a rational combined use of
immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved
in the responses to immunotherapy and how current drugs that target epigenetic regulators impact
on them.
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1. Introduction
Back in 1957 Burnet and Thomas proposed the theory of cancer immunosurveillance suggesting
that the immune system has the capacity to detect and destroy abnormal cells and may prevent the
growth of tumors. Cancer cells express cancer antigens, mainly produced by the accumulation of
mutations or re-expression of embryonic genes, which can be recognized by the adaptive immune
system. However, this strategy is not always effective in the eradication of cancer cells. Low mutational
rates or improper antigen presentation might result in the generation of insufficient functional tumor
antigen-specific T cells. There is also the possibility that tumor antigen–specific T cells are generated
but fail to infiltrate into the tumor parenchyma. In addition, a large number of immunosuppressive
mechanisms that typically operate within the tumor microenvironment can attenuate the immune
response. These immunosuppressive mechanisms are, in general, natural responses to prevent
autoimmunity during chronic antigen exposure. Eventually, cancer cells might also develop
mechanisms of resistance to the persistent action of the immune system. Cancer immunotherapies are
focused in boosting preexisting immune responses, such as immune checkpoint-oriented therapies,
or in the generation new immunological responses against tumors.
The recent success of immunotherapy in a subset of cancer patients suggest that the immune
system offers a feasible opportunity for therapeutic intervention. Unfortunately, despite showing
impressive responses in a percentage of cancer patients, more than half of the treated patients do
not experience clinical benefits. Thus, new strategies to improve the efficacy of these approaches
are needed. Emerging data suggest that epigenetic drugs can boost cancer patient’s responses
to immunotherapeutic treatments. In addition, understanding the role of chromatin in the
regulation of immune-related pathways might serve as a basis for the development on novel
immunotherapeutic strategies.
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2. Chromatin and Epigenetic Inhibitors
The genome is organized into chromatin structures that play critical roles in gene expression.
The fundamental unit of chromatin is the nucleosome, composed of two copies each of the core
histones H2A, H2B, H3, and H4, wrapped by DNA. Chromatin offers a physical barrier to the efficient
recruitment and processivity of the RNA Polymerase II (Poll l) and, thus, impedes transcription [1].
The N-terminal tails of histones are relatively accessible to enzymatic modifications, such as acetylation,
methylation, phosphorylation, ubiquitination, and sumoylation, and the cytosine residues of DNA
can be modified by methylation and hydroxymethylation. Chromatin covalent modifications are
dynamically regulated and result from an equilibrium between the action of enzymes that deposit the
mark and enzymes able to remove it. These modifications can influence the degree of condensation of
chromatin per se and/or facilitate the recruitment of structural or effector proteins, such as remodeling
complexes, that directly affect the condensation of chromatin [2]. Usually, the level of chromatin
compaction and the transcriptional status of genes is not determined by the presence of one single type
of modification but by the coincident action of several modifications present at a given region of the
genome. As a result of the combined action of modifications, certain areas of the genome are organized
into heavily condensed chromatin structures, such as centromeric regions, that offer little room for
transcriptional regulation. Other regions contain genes that are silenced, but that can be activated
by certain stimuli. These mechanisms, leading to transcriptional activation or repression, are likely
gene specific and highly influenced by the transcription factors bound at the regulatory regions of a
particular gene at a given time. The level of compaction of the chromatin influences the accessibility
of transcription factors to their responsive elements in the DNA and transcription factors, in turn,
have the ability to recruit chromatin-modifying enzymes that affect the structure of the chromatin.
Therefore, the interaction between transcription factors and chromatin structure is complex.
Over the last decades, highly potent and specific inhibitors of chromatin-modifying enzymes,
chromatin-related complexes, and proteins able to recognize specific histone marks have been
developed. Some of these inhibitors have shown promising results in cancer treatment in clinical
and/or preclinical studies.
DNA methylation is involved in gene repression and maintained by DNA methyltransferases
(DNMTs). The DNMTs inhibitors azacytidine (AZA) and decitabine (DAC) are the most successful
with the longest history of epigenetic drugs used in cancer treatment to date. These compounds are
nucleoside analogs that are incorporated into DNA during replication and form covalent adducts with
DNMTs depleting in this way the pool of active enzymes in the cell. AZA and DAC are currently
approved for the treatment of myelodysplastic syndrome and acute myeloid leukemia [3]. Traditionally,
it has been accepted that the therapeutic effects of DNA hypomethylating agents are mediated through
the reactivation of the expression of tumor suppressors, however recent findings suggest that the
mechanisms of action of these drugs are more complex.
Histone acetylation is involved in gene expression and is controlled by the action of histone
acetyltransferases (HATs) and histone deacetylases (HDACs). HDAC inhibitors have been approved
for the treatment of cutaneous or peripheral T cell lymphomas and multiple myeloma. HDACi have
shown limited single-agent activity in other malignancies [4]. Currently, several clinical trials are
ongoing to test the efficacy of both DNMTs and HDACs inhibitors both in hematologic and solid
tumors, many of them in combination with standard care drugs.
Histone acetylation stimulates gene transcription through the recruitment of effector factors
that, in turn, facilitate the proper recruitment and functionality of RNA polymerase II. Proteins
that contain bromodomains have the potential to bind to acetylated histones in the chromatin
and contribute to transcriptional activation [5]. Recently, inhibitors able to block the binding of
bromodomains to acetylated histones have been developed [6]. The first reported bromodomain
inhibitors (JQ1 and I-BET151) target the bromodomain of the BET family of proteins and have
demonstrated antiproliferative activity in preclinical studies [7,8]. Antiproliferative effects are mainly
mediated through the inhibition of the BET containing protein BRD4, that is essential for high-level
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expression of oncogenes that have very high levels of acetylation in their promoters [9]. Inhibitors of
BET proteins have recently entered early-stage clinical trials.
In addition to BRD4, the human proteome encodes at least 45 diverse bromodomain-containing
proteins [6]. These include several HATs such as CREBBP and EP300. Recently, dual inhibitors of the
bromodomains of CREBBP and EP300 have been developed and preclinical studies suggest that they
have therapeutic potential [10–15]. Inhibition of the CREBBP/EP300 bromodomains likely impedes
the proper binding of these factors to acetylated chromatin which, in turn, prevents the acetylation of
histones leading to a decrease in gene expression [12].
In addition to DNMTs, HDACs and bromodomain inhibitors, drugs that inhibit other classes of
epigenetic regulators have been described, such as inhibitors of histone methyltransferases (HMTs)
and demethylates (HDMTs). Inhibitors targeting the histone methyltransferases DOT1L and EZH2, as
well as the demethylase KDM1 (also known as LSD1), have recently entered the first stages of clinical
trials in cancer therapy and might hold the potential to modulate the cancer-immune system axis [16].
3. Reinvigoration of Exhausted T Cells
During chronic antigen exposure in cancer T cells become exhausted and dysfunctional [17].
As discussed above, rather than anomalous, this process seems to be a natural safeguard mechanism
that impairs prolonged immune responses that may result in autoimmunity. Exhausted T cells exhibit
defective proliferative capacities, reduced cytokine production and diminish lytic functions. The loss of
these important properties is coincident with the upregulation of several surface receptors, including
PD-1 and CTLA-4. Concomitantly, the expression of PD-1 ligands PD-L1 and PD-L2 in tumor cells is
induced by cytokines and inflammatory factors, such as interferon gamma (IFNγ), mostly secreted by
activated T cells infiltrated in the tumor. After ligand binding, PD-1 inhibits kinase-signaling pathways
involved in T-cell activation. Accordingly, antibodies that block the interaction of CTLA-4 or PD-1 with
their ligands are able to reinvigorate exhausted T cells and have shown long-term favorable responses
in a percentage of cancer patients, including complete tumor regression and remission in patients with
far-progressed cancers that were refractory to standard treatments [18–20].
Favorable responses to anti-PD-1/PD-L1 therapies typically correlate with high levels of PD-L1
expression in tumors [21,22]. There is also a strong association between low DNA methylation status
of the PD-L1 promoter in tumors and poor survival of acute myeloid leukemia (AML) patients,
suggesting that DNA methylation may block the induction of PD-L1 in tumors in response to IFNγ
or other immunological cues [23]. Clinical trials have shown that a small percentage of NSCLC
patients previously treated with the DNA hypomethylating agent AZA show improved responses
to anti-PD1/PD-L1 therapies [24]. AZA treatment alone or in combination with other epigenetic
inhibitors improves the therapeutic efficacy of anti-PD-L1 and anti-CTLA4 treatments in mouse
models of melanoma and ovarian cancer [25,26]. A potential explanation for this outcome is the
increase in PD-L1 expression caused by AZA in cancer cells (Figure 1) [27,28]. Upregulation of PD-L1,
PD-L2, PD-1, and CTLA4 expression has been also detected in myelodysplastic syndromes patients
treated with DNA hypomethylating agents and has been associated with the emergence of resistance to
AZA [29]. Overall, these data might provide a rationale to combine DNA hypomethylating agents with
PD-1/PD-L1 immune checkpoint blockade to avoid immune escape through PD-L1 upregulation after
exposure to DNA hypomethylating agents. However, it should be taken into account that the effects of
AZA in the expression of immunomodulatory signatures are diverse and additional aspects might
be involved in boosting the anti-tumor immune responses mediated by anti-PD-L1 and anti-CTLA4
treatments, as explained below.
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antigens to T-cells mediating their activation. Activated T cells migrate to the tumor and recognize 
cancer cells that present cancer-associated antigens. Activated T cells carry out effective functions to 
eliminate cancer cells, among them secretion of IFNγ that will promote apoptotic effects in cancer 
cells. Sustained exposure to IFNγ leads the expression of PD-L1 in cancer cells and T cell exhaustion. 
Blue arrows indicate critical steps activated or blocked by epigenetic drugs. 
Similar to AZA, HDAC inhibitors upregulate the expression of PD-L1 and PD-L2 in melanoma 
cells providing a rationale for the reduced tumor progression and increased survival of HDAC 
inhibitors and PD-1 blockade combinations observed in a murine model of melanoma compared with 
single-agent treatments [30]. However, due to the pleiotropic effects of epigenetic regulators (Table 1), 
combinatorial therapies with immune checkpoints might have more complex responses than 
anticipated. For example, epigenetic drugs are also likely to have direct effects in the epigenome of 
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inhibitor entinostat has been reported to cause eradication of tumors and metastasis in a mouse model 
of breast cancer, mainly through inhibition of granulocytic myeloid-derived immune suppressive 
cells (MDSCs) [31]. Additionally, it has been proposed that HDAC inhibitors enhance the response 
to PD-1 blockade in multiple lung tumor models through the stimulation of T-cell chemokine 
expression [32]. Despite the relatively low existing understanding of the mechanisms of action of 
HDACs and DNMTs inhibitors in the immune system, the promising results obtained in preclinical 
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Table 1. Described effects of inhibitors of the indicated epigenetic targets and targeted domains in
immuno-oncology-related pathways.
Target Domain Immuno-Modulatory Effects
DNMTs Methyltransferase
Upregulation of PD-L1/PD-L2 in cancer cells
Upregulation of cancer testis antigens (CTAs)
Upregulation of genes of the MHC presentation pathway
Reactivation of repetitive elements (including ERVs)
HDACs Deacetylase
Upregulation of PD-L1/PD-L2 in cancer cells
Upregulation of cancer testis antigens (CTAs)
Upregulation of genes of the MHC presentation pathway
Reactivation of repetitive elements
Upregulation of T cell chemokine expression
BRD4 Bromodomain Downregulation of PD-L1 in cancer cells
EP300 Acetyltransferase Bromodomain Downregulation of FOXP3 in Tregs
Eventually, epigenetic inhibitors can be used to downregulate the expression of PD-1 or PD-L1
alleviating the process of T-cell exhaustion. The bromodomain inhibitor JQ1 suppresses PD-L1 gene
expression in ovarian cancer cell lines that express high levels of this gene and increases the activity
of cytotoxic T cells limiting tumor progression in a mouse model of ovarian cancer (Figure 1) [33].
Importantly, JQ1 is able to revert the induction of PD-L1 mediated by IFNγ in vitro, suggesting that
it could also prevent the induction of PD-L1 expression by IFNγ secreted by infiltrating T cells [33].
In addition, BRD4 inhibitors have also shown antiproliferative effects in ovarian cancer cells [34].
Therefore, JQ1 might have dual anti-tumor actions: it slows down the proliferation of tumors and
prevents T cell exhaustion.
Unfortunately, despite the impressive results achieved in some patients, the majority of patients
do not respond to PD-1/PD-L1 checkpoint blockade, with many patients demonstrating a transient
restoration of T cell function followed by disease relapse [18]. Although checkpoint blockade
temporarily restores T cell effector function, the epigenetic landscape of exhausted T cells, which
significantly differs from non-exhausted T cells, is not reinvigorated with treatment and might be
responsible for the reversion back to an exhausted state after withdrawal of treatment [35]. It is
still unknown whether patients that respond to treatment might have exhausted T cells with a
less-committed epigenetic landscape that facilitates their reinvigoration at the epigenetic level. In any
case, epigenetic drugs could be used in combination with PD-1/PD-L1 checkpoint blockade to
reinvigorate the epigenome of exhausted T cells and achieve durable responses.
4. Antigen Presentation and HLA Expression
Recognition of cancer cells by tumor-specific T cells is achieved by the presentation of antigenic
peptides on major histocompatibility complex (MHC) class I molecules on the surface of cancer cells.
These cancer-specific antigens might be the result of mutagenesis, cancer-restricted alternative splicing,
or re-expression of embryonic antigens typically silent in healthy adult tissues. Downregulation of the
expression of tumor-associated antigens and MHC class I genes constitutes a common mechanism
of immune evasion. DNA methylation appears to be involved in this process, as judged by the
upregulation in the expression of cancer testis antigens (CTAs), which are expressed in placenta and
testis, but not in the rest of adult healthy tissues, and MHC class I genes by DNMT inhibitors in
cancer cells [36,37]. AZA and HDAC inhibitors have been also described to cause the reactivation
of repetitive elements such as endogenous retroviruses and transposable elements [26,38,39] which
could eventually contribute to introduce mutations and subsequent production of new antigens that
can be potentially targeted by the immune system. In addition, the promoters of several CTAs are
enriched in the repressive chromatin mark H3K27me3 in lung cancer cell lines that express low levels
of these genes. Accordingly, inhibition of EZH2, the enzyme involved in H3K27me3 deposition,
potentiates the induction of CTLAs by DAC in these cell lines [40]. Additionally, knockdown of
the demethylases KDM1 or KDM5B also enhanced DAC-mediated activation of these cancer–testis
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genes [40]. These demethylases specifically remove H3K4 methylation, a modification involved in
gene activation, and although their knockdown caused markedly-increased levels of H3K4me2 at
several CTAs the activation of these genes was only observed in combination with DAC. These results
highlight the complexity of the interplay between histone and DNA modifications to regulate gene
expression in living cells. Importantly, promising results have been recently reported for the first Phase
I clinical trial testing an inhibitor of KDM1 in acute leukemia [41], and additional clinical trials for
KDM1 inhibitors on sickle cell disease, small cell lung cancer, and other advanced malignancies have
been recently launched (NCT02712905, NCT02913443 and NCT03132324, https://clinicaltrials.gov).
Inhibitors against KDM5 that show anti-cancer properties in preclinical models have also been recently
developed [42]. Testing potential effects of KDM1 and KDM5 inhibitors in boosting tumor antigenicity
is granted as these inhibitors move into the clinic and more knowledge is gained in preclinical models.
Finally, similarly to DNMT inhibitors, HDAC inhibitors have also been found to upregulate the
expression of cancer-specific antigens and components of the tumor antigen processing and MHC
presentation pathway [43].
Despite the fact that tumor cells can present antigens, they have very limited capacity to activate
T cells. In fact, dendritic cells (DCs) are the antigen-presenting cells that play a pivotal role in the
activation of T cells by cancer-associated antigens (Figure 1). In addition to proper antigen presentation
by the MHC, T cell activation requires further stimulation by the co-stimulatory surface molecules
B7 on DCs and CD28 on T cells. DCs can sample tumor antigens through the capture of dying tumor
cells and phagocytosis of small quantities of membrane from live cells [44]. Therefore, it is possible
that epigenetic inhibitors that have apoptotic effects on tumors will also facilitate antigen presentation
by DCs and subsequent activation of T cells. Additional potential effects of epigenetic drugs in the
expression of critical molecules involved in antigen presentation and stimulation of T cells by DCs
remain mainly unexplored.
5. Adoptive Cell Transfer and Expression of Critical Tumor Neoantigens
Adoptive cell transfer (ACT) consists of purification, in vitro modification, expansion, and
infusion back into patients of therapeutically-relevant immune cell types. It has been shown that
adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) mediates durable
complete regressions in some patients with metastatic melanoma [45]. One promising strategy to boost
the efficiency of ACT is to administer T cells that have been genetically engineered to express a T-cell
receptor (TCR) that recognizes a specific tumor antigen or a chimeric antigen receptor (CAR) that has
been artificially constructed to contain the tumor antigen-binding domain of an antibody fused with
a T-cell signaling domain [46]. The success of these therapies partially depends on the expression
of a specific and immunogenic antigen in cancer cells that functions as a target for the engineered T
cell. The majority of to-date targeted tumor antigens are self-antigens, normally expressed during
development and aberrantly expressed by tumors. In this regard, inhibitors of repressive chromatin
factors have been proven to induce the expression of some of these antigens. DNA hypomethylating
agents induce expression of the antigen NY-ESO-1 in colorectal cancer cells improving the efficacy
adoptive T cell therapy against this antigen [47]. Similarly, HDAC inhibitors cause the upregulation of
the antigen NKG2DL in ovarian cancer cell lines facilitating their immune recognition by chimeric
NKG2D CAR T cells [48].
Importantly, infused T cells must be able to resist mechanisms of exhaustion. Recently,
Sen et al. [49] characterized enhancer regions involved in the induction of PD-1 expression during
exhaustion by comparing the epigenetic landscape of non-exhausted and exhausted T cells. Of
relevance, introducing genetic deletions in these enhancers regions dramatically reduced PD-1
expression. Thus, generating antigen-oriented engineered T cells that also contain mutations in
the PD-1 enhancer might be a potential strategy to prevent exhaustion of these cells in ACT strategies.
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6. Modulating Regulatory T cells
Regulatory T cells (Tregs) constitute an additional strategy to prevent autoimmunity by
suppressing aberrant immune responses against self-antigens. However, these cells can also suppress
anti-tumor immune responses. Tregs mediate their suppressive activity by several mechanisms, which
include suppression of antigen-presenting cells via CTLA-4 and secretion of inhibitory cytokines.
Infiltration of a large number of Tregs into tumor tissues is often associated with poor prognosis.
Accumulating evidence suggests that Treg depletion might be able to reestablish and enhance
anti-tumor immune responses [50].
Tregs express high levels of the transcription factor FOXP3 that controls the gene expression
programs involved in Treg function. The histone acetyltransferase EP300 acetylates FOXP3 increasing
its stability by preventing ubiquitin-dependent degradation [51] and it is also likely that it participates
as a cofactor in FOXP3-dependent transcription through histone acetylation. Conditional deletion of
EP300 in Tregs impairs Treg cell suppressive functions and peripheral Treg cell induction, limiting
tumor growth in mice [52]. The EP300 HAT inhibitor C646 [53] recapitulates these effects suggesting
that chemical inhibition of EP300 offers a good opportunity to modulate Treg function [53]. However,
C646, which is the most potent and selective EP300 HAT inhibitor reported this far, shows low potency
in cells, likely due to its affinity for cysteine-rich proteins [54]. More recently, inhibitors of the EP300
bromodomain have been developed. Treatment of Tregs with these inhibitors led to a reduction in
FOXP3 expression both at protein and transcript levels, which was coincident with lower levels of
FOXP3 acetylation and lower levels of histone acetylation at the FOXP3 locus [14]. The fact that
the EP300 bromodomain is required for the proper binding of EP300 to chromatin [12] and that
bromodomain inhibitors do not affect EP300 HAT activity [14], suggest that FOXP3 acetylation is
likely to take place in the chromatin (Figure 2). FOXP3·has been described to interact with several
chromatin-related proteins [55,56] that might be pharmacological candidates to modulate FOXP3
activity and Treg function.
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7. Rewiring the Interferon Pathway
Interferons are cytokines with a long history of involve ent in the development and treatment
of cancer. Of the three major types of interferons, type I FNs (most studied IFNα and IFNβ) can
be produced by most cell types in the organisms, while type II (IFNγ) and III IFNs are restricted
to specific cell types, such as T cells and natural killer cells (NK) [57]. The binding of interferons
to their transmembrane receptors stimulates the activation of associated JAK tyrosine kinases that
result in phosphory ation and activati n of signal transducers and activators of transcription (STATs)
which dimerize and translocate to the nucleus to drive the expression of IFN-stimulated genes. IFNs
regulate multiple facets of antitumor biology. They directly affect the immune system by promoting
the antitu or activity of T cells, NK cells, and DCs, and inhibiting the activity of immune-suppressive
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cells, such as Tregs. In addition, IFNs have important effects in tumor cells including inhibiting cell
cycle, promoting apoptosis and improving antigen expression and presentation. Eventually, tumors
might become resistant to the action of IFNs in several ways including deletion of IFN type I genes
and alteration of JAK-STAT components of the IFN-induced signaling [57]. Epigenetic therapies might
help to restore the sensitivity of tumors to IFN, or even stimulate IFN production by tumor cells or
immune cells in the tumor microenvironment.
The molecular mechanism by which DNA methyltransferases inhibitors show clinical efficacy is of
intense debate and several mechanisms have been proposed (as discussed above). The most accepted
mechanism is that it reactivates the expression of tumor suppressors by reversing the abnormal DNA
methylation in their promoters. However, the prolonged time to response observed in patients, and the
lack of a global DNA methylation profiling predictive signature for response, suggests the existence of
other mechanisms beyond the demethylation of tumor suppressor’s promoters. In NSCLC, breast,
colorectal, and ovarian cancer cell lines, AZA treatment upregulates genes and pathways related to
IFN and immunity [27,28]. Two recent papers show that AZA stimulates these IFN-related signatures
through the induction of endogenous retroviruses (ERVs) that are silenced through DNA methylation
in cancer cells [26,39]. Loss of DNA methylation correlates with re-expression of ERVs through
bidirectional transcription that results in the production of double stranded RNAs (dsRNA). These
dsRNAs are sensed by viral defense proteins that, in turn, stimulate the production of IFN and the
activation of anti-viral, anti-proliferation, and pro-apoptotic pathways in cancer cells (Figure 3) [26,39].
Furthermore, the production of IFN might contribute to facilitate the infiltration and activation of T
cells into the tumor microenvironment, stimulate tumor antigen presentation to T cells by dendritic
cells and have a negative impact on Treg proliferation [57]. In addition to PD-L1 re-expression, the
stimulation of IFN production in cancer cells through re-activation of endogenous retroviruses provides
an alternative mechanisms for the improved therapeutic efficacy of anti-PD-L1 or anti-CTLA4 and
AZA combinations [25,26] in which anti-PD-L1 or anti-CTLA4 therapy contributes to alleviate T cell
exhaustion caused by prolonged exposure to AZA-induced IFN.
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that, in turn, stimulate the production of IFN and the activ tion of an i-viral, anti-pr liferation, and 
pro-apoptotic pathways in cancer cells (Figure 3) [26,39]. Furthermore, the production of IFN might 
contribute to facilitate the infiltration and activation of T cells into the tumor microenvironment, 
stimulate tumor antigen presentation to T cells by dendritic cells and have a negative impact on Treg 
proliferation [57]. In addition to PD-L1 re-expression, the stimulation of IFN production in cancer cells 
hrough re-activation o  endogenous retroviruses provides an alternative mechanisms for the improved 
therapeutic efficacy of anti-PD-L1 or anti-CTLA4 and AZA combinations [25,26] in which anti-PD-L1 
or anti-CTLA4 therapy contributes to alleviate T cell exhaustion caused by prolonged exposure to 
AZA-induced IFN. 
 
Figure 3. DNMTs inhibitors activate the expression of endogenous retroviruses in cancer cells. 
Treatment with DNMTs inhibitors (blue arrow) causes loss of DNA methylation in the long terminal 
repeats (LTR) of endogenous retroviruses (ERVs) and activation of bidirectional transcription, which 
leads to the formation of double-stranded RNA (dsRNA). dsRNA are sensed in the cytoplasm by 
cytosolic receptors MDA5/RIG-I/LTRs that initiate signaling cascades to mediate the phosphorylation 
of interferon responsive factors (IRFs) that, in turn, activate the expression of target genes in the 
nucleus, including IFNs. INFs activate JAK/STAT-dependent signaling pathways, which result in the 
induction of interferon stimulated genes (ISGs). 
Figure 3. DNMTs inhibitors activate the exp sion of endogenous retroviruses in cancer cells.
Treatment with DNMTs inhibitors (blue arrow) causes loss of DNA methylation in the long terminal
repeats (LTR) of endogenous retroviruses (ERVs) and activation of bidirectional transcription, which
leads to the formation of double-stranded RNA (dsRNA). dsRNA are sensed in the cytoplasm by
cytosolic receptors MDA5/RIG-I/LTRs tha initia e signaling cascad t mediate the phosphorylation
of interferon responsive factors (IRFs) that, in turn, activate the expression of target genes in the nucleus,
including IFNs. INFs activate JAK/STAT-dependent signaling pathways, which result in the induction
of interferon stimulated genes (ISGs).
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Importantly, the reactivation of dsRNAs and concomitant immunological signatures hold
unprecedented predictive value for patient response. Comparison of the basal expression of
AZA-induced IFN-related genes within a collection of ovarian, breast, colon, and lung cancers reveals
the existence of low- and high-expressing groups of patients [26]. Interestingly, highly-expressing
subtypes appear more sensitive to immune checkpoint therapy, raising the possibility that treatment
of patients with a low expression signature with AZA improves responses to immune checkpoint
inhibition. Moreover, monitoring the re-expression of dsRNA might be a better predictor of patient
response than monitoring DNA methylation levels [39].
8. Conclusions and Future Directions
Increasing evidence suggests that epigenetic drugs can improve the therapeutic responses to
cancer immunotherapies. As reviewed here, immunotherapies might also contribute to palliate
acquired resistance to the treatment with epigenetic drugs. Perhaps the most attractive potential is
the fact that several epigenetic inhibitors can block the proliferation and viability of cancer cells while
potentiating the actions of the immune system. However, the inhibition of epigenetic regulators has
pleiotropic effects that affect multiple pathways both in cancer cells and immune cells and, therefore,
dissecting the molecular mechanisms involved in the responses is not straightforward. In addition to
DNMT and HDAC inhibitors, which are the epigenetic drugs with longer therapeutic history, inhibitors
of other classes of epigenetic regulators are emerging and might show immunomodulatory properties.
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